Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Chen Xiaoping
- Target Recruit Count
- 160
- Registration Number
- NCT06420440
Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Zhiyong Huang
- Target Recruit Count
- 20
- Registration Number
- NCT06417606
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, China
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-10
- Target Recruit Count
- 62
- Registration Number
- NCT06409637
- Locations
- 🇨🇳
Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,, Guangzhou, Guangdong, China
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06406634
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT06389500
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 469
- Registration Number
- NCT06371157
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shanxi Cancer Hospital, Taiyuan, Shanxi, China
CARE1 Pragmatic Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1250
- Registration Number
- NCT06364631
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06362317
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, Beijing, China
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 300
- Registration Number
- NCT06333561
- Locations
- 🇨🇳
Chinese PLA General hospital, Beijing, Beijing, China
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Hyogo Medical University
- Target Recruit Count
- 25
- Registration Number
- NCT06318286
- Locations
- 🇯🇵
Hyogo Medical University Hospital, Nishinomiya, Hyogo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.